ATLANTA, GEORGIA—Arsenic could play a key role in perfecting gentle but curative regimens for acute promyelocytic leukaemia, according to Italian researchers reporting to the 2012 American Society of
ATLANTA, GEORGIA—Arsenic could play a key role in perfecting gentle but curative regimens for acute promyelocytic leukaemia, according to Italian researchers reporting to the 2012 American Society of Hematology annual meeting. Professor Francesco Lo Coco from the University Tor Vergata in Rome told Peter Goodwin how the use of arsenic to accompany retinoic acid (ATRA) rather than chemotherapy might be the most effective and least toxic regimen of all, completing the conversion of this disease from being highly fatal — as it was in the past — to highly curable.
LISTEN
[audio:https://www.audiomedica.com/podcasting/oncology/121217FrancescoLoCocoPODCASTLoRes.mp3]